Treatment Escalation vs Immediate Initiation of Highly Effective Treatment for Patients With Relapsing-Remitting Multiple SclerosisTim Spelman, Jan Lycke, Melinda Magyari et al.|JAMA Neurology|2021Cited by 237
Initial high-efficacy disease-modifying therapy in multiple sclerosisMathias Due Buron, Melinda Magyari, Thor Ameri Chalmer et al.|Neurology|2020Cited by 160
Rituximab vs Ocrelizumab in Relapsing-Remitting Multiple SclerosisIzanne Roos, Vincent Van Pesch, Olga Skibina et al.|JAMA Neurology|2023Cited by 62
Comparative effectiveness of teriflunomide and dimethyl fumarateMathias Due Buron, Melinda Magyari, Thor Ameri Chalmer et al.|Neurology|2019Cited by 45
Real-world experience of cladribine treatment in relapsing-remitting multiple sclerosis: A Danish nationwide studyPer Soelberg Sørensen, Melinda Magyari, Luigi Pontieri et al.|Multiple Sclerosis and Related Disorders|2022Cited by 42